COMMUNIQUÉS West-GlobeNewswire

Singular Genomics Announces 1-for-30 Reverse Stock Split
21/06/2024
SAN DIEGO, June 21, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and [...]
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
21/06/2024
TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, welcomes Dr. [...]
Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
21/06/2024
WORCESTER, Mass., June 21, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell [...]
Inteleos’ Point-of-Care Ultrasound Certification Academy Launches Comprehensive Maternal Fetal Health Certification
21/06/2024
New OB 2nd/3rd Trimester Certificate Now Available, Completes Suite of Maternal Fetal Health Certification Products ROCKVILLE, Md., June 21, 2024 (GLOBE NEWSWIRE) -- Inteleos, a global non-profit healthcare [...]
Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024
21/06/2024
Daix (France), Long Island City (New York, United States), on June 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral [...]
Résultats des votes de l’Assemblée Générale Mixte des actionnaires réunies le 20 juin 2024
21/06/2024
Daix (France), Long Island City (New York, Etats-Unis), le 21 juin 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites [...]
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
21/06/2024
— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZAQLA ® (fruquintinib) is the first novel targeted therapy in the EU for metastatic [...]
Standards Alliance Awards Inteleos Foundation to Expand Ultrasound Training in Kenya
21/06/2024
ROCKVILLE, Md., June 21, 2024 (GLOBE NEWSWIRE) -- The Inteleos Foundation, a public non-profit organization driving positive health outcomes through education in medical imaging, received a three-year, $180,000 subaward [...]
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
21/06/2024
Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented BOSTON, June 21, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” [...]
ALK upgrades its full-year revenue and earnings outlook
21/06/2024
ALK ( ALKB:DC / OMX: ALK B / AKBLF ) today announced that the full-year financial outlook has been upgraded to reflect better than expected sales performance in Q2 and an improved outlook for the remainder of the year. [...]
ALK provides update on regulatory process for the house dust mite allergy tablet in China
21/06/2024
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that it has decided to withdraw the Biologic License Application (‘BLA’) for its house dust mite (‘HDM’) sublingual allergy immunotherapy tablet in China. ALK will [...]
BioSenic signs a new subscription agreement for a maximum of EUR 2.1M in convertible bonds
21/06/2024
PRESS RELEASE – PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, June 21, 2024 6.00pm CEST – BioSenic (Euronext Brussels and Paris: BIOS) , the clinical stage company specializing in serious autoimmune and [...]
BioSenic signe une nouvelle convention de souscription pour un maximum de 2,1 millions d'euros en obligations convertibles
21/06/2024
COMMUNIQUÉ DE PRESSE – INFORMATION PRIVILÉGIÉE Mont-Saint-Guibert, Belgique, le 21 juin 2024, 18h00 CEST – BIOSENIC (Euronext Bruxelles et Paris : BIOS), la société en phase clinique spécialisée dans les maladies auto- [...]
Psychemedics Unveils Inaugural Insights Report: Revealing Drug Trends Through Hair Testing
21/06/2024
DALLAS, June 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, proudly presents its inaugural Insights Report. This groundbreaking report offers a [...]
Sharecare enters into definitive agreement to be acquired by Altaris
21/06/2024
Sharecare shareholders to receive $1.43 per share in cash Transaction will deliver significant immediate cash value to stockholders upon closing, best positions Sharecare to continue to deliver exceptional service to [...]
Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting
21/06/2024
Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting Halle (Saale) / Munich, Germany, June 21, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon, or the Company [...]
Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences
21/06/2024
– Collaboration advancing Palisade Bio’s precision medicine approach through access to cutting-edge expertise and tools in bioinformatics – Candidate PDE4-related biomarkers overlapping with UC pathophysiology have been [...]
Starton Therapeutics Announces 100% Partial Response or Better in Multiple Myeloma Patients in Interim, Top-line Data from STAR-LLD Phase 1b Clinical Trial
21/06/2024
100% of patients enrolled achieved a partial response or better Milder and less frequent drug-related adverse events were observed compared to those associated with Revlimid ® No grade 3 or greater adverse events in [...]
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
21/06/2024
Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease Company Anticipates Six Month Review and Potential Launch in Early [...]

Pages